2019
DOI: 10.17696/2318-3691.26.1.2019.1222
|View full text |Cite
|
Sign up to set email alerts
|

Uso do eculizumab na síndrome hemolítico urêmica atípica associada a comprometimento da função renal: revisão integrativa

Abstract: Introdução: a Síndrome Hemolítico Urêmica é uma doença rara e grave que se define pela anemia hemolítica microangiopática não imune, trombocitopenia e insuficiência renal aguda. Objetivo: identificar informações disponíveis na literatura acerca do uso do eculizumab no tratamento da síndrome hemolítico urêmica atípica com comprometimento da função renal associado. Material e métodos: trata-se de uma revisão integrativa realizada nas seguintes bases de dados: Literatura LatinoAmericana e do Caribe em Ciências da… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 13 publications
0
1
0
Order By: Relevance
“…In the second case, eculizumab therapy was introduced 15 days after the initial suspicion of aHUS. Eculizumab, a human monoclonal antibody that stops the activation of the C5 complement component and the final complement formation, has recently been shown to be effective in the treatment of aHUS [ 28 30 ]. It helps in the recovery of kidney function and can completely change the prognosis of this potentially catastrophic disorder [ 31 ].…”
Section: Case Discussionmentioning
confidence: 99%
“…In the second case, eculizumab therapy was introduced 15 days after the initial suspicion of aHUS. Eculizumab, a human monoclonal antibody that stops the activation of the C5 complement component and the final complement formation, has recently been shown to be effective in the treatment of aHUS [ 28 30 ]. It helps in the recovery of kidney function and can completely change the prognosis of this potentially catastrophic disorder [ 31 ].…”
Section: Case Discussionmentioning
confidence: 99%